NYU Langone Medical Center cardiologists present at ACC 60th Annual Scientific Session

April 05, 2011

Cardiologists from the Cardiac & Vascular Institute at NYU Langone Medical Center presented new research findings at the American College of Cardiology 60th Annual Scientific Session held April 2-5, 2011 in New Orleans, Louisiana. Significant research findings presented by NYU Langone cardiologists included:

The Relationship between Bleeding and Mortality in Patients on Dual Antiplatelet Therapy vs. Aspirin Alone: Results from the CHARISMA Trial
Author: Jeffrey S. Berger, MD, MS, FACC, assistant professor, Medicine and director of Cardiovascular Thrombosis


Little is known about the association between bleeding and death and the actual cause of death in patients on different antiplatelet agents. Researchers investigated the association between bleeding and mortality to assess whether this association differs in patients on dual antiplatelet therapy (DAPT) versus aspirin alone. Researchers examined the association between moderate or severe bleeding and all-cause, cardiovascular and cancer mortality in 15,603 patients with cardiovascular disease or multiple risk factors enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial (CHARISMA). The study shows patients with moderate or severe bleeding had a higher incidence of all-cause, cardiovascular and cancer mortality. After multivariable adjustment, moderate/severe bleeding remained independently associated with not only all-cause mortality but cancer mortality as well. There was a significant interaction between bleeding and potency of antiplatelet therapy for all-cause, cardiovascular, and cancer mortality. In subjects on aspirin alone, moderate/severe bleeding was associated with all-cause, cardiovascular, and cancer mortality, but not in subjects on dual antiplatelet therapy. The study shows in stable patients, moderate or severe bleeding is associated with a significantly increased risk of all-cause, cardiovascular and cancer mortality. However, this risk differed in patients on aspirin alone versus dual antiplatelet therapy.

Abstract 1101-142: Monday, April 4, 2011, 9:30 AM

Learn more: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=292bd6a6-c372-4762-beb0-e195423fd9e9&cKey=61d2804b-4770-4012-8909-2e3b87d1d635&mKey=%7b79E691F3-9BF2-4C60-B958-A23D68B60921%7d

Six-Year Outcomes of Patients Treated with DES, BMS or Medical Therapy in the OAT Trial
Principal Investigator: Judith S. Hochman, MD, Harold Snyder Family Professor of Cardiology and director, Cardiovascular Clinical Research


The Occluded Artery Trial (OAT) is a randomized study of routine percutaneous coronary intervention (PCI) or optimal medical therapy (MED) alone for the treatment of a totally occluded infarct-related artery 3 to 28 days after myocardial infarction in subjects who met a high-risk criterion. The study did not show any difference in death, reinfarction and congestive heart failure between study groups after a 6-year mean follow-up. Although the majority of percutaneous coronary intervention patients in the study were treated with bare metal stents (BMS), drug eluting stents (DES) were also implanted in the latter part of the study. Researchers performed an exploratory analysis of long-term outcomes for drug eluting stent deployment versus bare metal stents of the target occlusion in the percutaneous coronary intervention group vs. medical therapy in the OAT Trial. They compared the clinical outcomes of percutaneous coronary intervention patients with drug eluting stents, bare metal stents and medical therapy (DES n=79, BMS n=393, MED n=552) up to a maximum follow-up of 6 years (mean survivor follow-up 5.1 years). In the analysis, the 6-year occurrence of death, reinfarction and class IV congestive heart failure was similar (20.4% of DES, 18.9% of BMS and 18.4% of MED). During the follow-up period, 33.4% of DES, 44.4% of BMS and 48.1% of MED patients developed angina. The rate of revascularization during follow up was 11.3% of DES, 20.5% of BMS and 22.5% of MED. There is no suggestion of reduced long-term risk of death, reinfarction or class IV congestive heart failure with drug eluting stent usage compared to bare metal stent or medical treatment alone. In the study, an association between drug eluting stent use and freedom from angina and revascularization relative to medical therapy is suggested. Researchers stress the data must be interpreted with caution due to the small number of patients treated with drug eluting stents and the non-randomized nature of the analysis.

Abstract Number 2508-532: Monday, April 4, 2011, 9:30 AM

Learn more: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=3728b926-32be-46ce-8909-6b0ff4988bc1&cKey=e39bdba7-f5c1-4c19-86c2-a337db6c7406&mKey=%7b79E691F3-9BF2-4C60-B958-A23D68B60921%7d

Platelet Size is an Excellent Surrogate for Increased Platelet Activity
Authors: Michael Merolla, Medicine; Michael A. Nardi, MS, associate professor, Pediatrics; Liang Hu, Hematology; Caron B. Rockman, MD, associate professor, Surgery; Jeffrey S. Berger, MD, MS, FACC, assistant professor, Medicine and director of Cardiovascular Thrombosis
Increased platelet activity is associated with an increased risk of cardiovascular morbidity and mortality. A variety of techniques used in laboratory research and clinical practice measure platelet activity, yet, there is no accepted gold standard. Mean platelet volume (MPV) is easily obtained as part of routine clinical laboratory testing. It is quick and inexpensive. Researchers investigated the association of mean platelet volume with other measurements of platelet activity. In the study, 154 patients with and without vascular disease were recruited for analysis. In addition to measuring mean platelet volume, researchers measured platelet count, immature platelet fraction, percent reticulated platelets, PAC-1 platelet marker staining, and impedance aggregometry. The study shows mean platelet volume is associated with several markers of platelet activity, most notably, markers of increased platelet turnover. Future studies should investigate whether mean platelet volume obtained as part of routine laboratory testing could identify patients at risk for cardiovascular events and help guide anti-platelet and other pharmacologic risk-factor reduction strategies.

Abstract 1146-95: Tuesday, April 5, 2011, 9:30 AM

Learn more: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=62ca41b8-339e-421d-a73f-1f7b4597ec24&cKey=e03e264d-e96d-4016-9118-cd44554d84d1&mKey=%7b79E691F3-9BF2-4C60-B958-A23D68B60921%7d
-end-
About NYU Langone Medical Center

NYU Langone Medical Center, a world-class patient-centered integrated academic medical center, is one of the nation's premier centers for excellence in health care, biomedical research, and medical education. Located in the heart of Manhattan, NYU Langone is comprised of three hospitals--Tisch Hospital, a 705-bed acute-care tertiary facility, Rusk Institute of Rehabilitation Medicine, the first rehabilitation hospital in the world, with 174 beds and extensive outpatient rehabilitation programs, and the 190-bed Hospital for Joint Diseases, one of only five hospitals in the world dedicated to orthopaedics and rheumatology--plus the NYU School of Medicine, one of the nation's preeminent academic institutions. For more information, visit http://www.med.nyu.edu/.

NYU Langone Medical Center / New York University School of Medicine

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.